↓ Skip to main content

The effect of electroacupuncture combined with donepezil on cognitive function in Alzheimer’s disease patients: study protocol for a randomized controlled trial

Overview of attention for article published in Trials, July 2017
Altmetric Badge

Mentioned by

news
1 news outlet

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
125 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The effect of electroacupuncture combined with donepezil on cognitive function in Alzheimer’s disease patients: study protocol for a randomized controlled trial
Published in
Trials, July 2017
DOI 10.1186/s13063-017-2052-y
Pubmed ID
Authors

Weina Peng, Jing Zhou, Min Xu, Qing Feng, Lulu Bin, Zhishun Liu

Abstract

Alzheimer's disease is a progressive neurodegenerative disease. Although some of the current treatments offer some symptomatic relief, this disease cannot be cured at present. Electroacupuncture may be effective for Alzheimer's disease for cognitive function, but the evidence for its effectiveness is still limited. The aim of this study is to evaluate the add-on effect of electroacupuncture to donepezil for improving the cognitive function of Alzheimer's disease. A total of 334 participants with Alzheimer's disease will be randomly assigned to either an electroacupuncture combined with donepezil group or a donepezil group with a ratio of 1:1. Participants in the electroacupuncture combined with donepezil group will receive electroacupuncture in addition to donepezil for 12 weeks and will keep taking donepezil for the following 24 weeks. Participants in the control group will take donepezil only. The primary outcome is the change from baseline in the total score of the Alzheimer's Disease Assessment Scale-cognition at week 12. A follow-up will be conducted 24 weeks after the treatment. We expect to verify the hypothesis that acupuncture in addition to donepezil is better than donepezil in improving the cognitive function of patients with Alzheimer's disease. This trial has a limitation that participant blinding is impossible. Clinical Trials.gov: ID: NCT02305836 . Registered on 13 November 2014.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 125 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 125 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 22 18%
Student > Bachelor 15 12%
Other 9 7%
Student > Ph. D. Student 8 6%
Researcher 7 6%
Other 14 11%
Unknown 50 40%
Readers by discipline Count As %
Medicine and Dentistry 22 18%
Nursing and Health Professions 14 11%
Neuroscience 8 6%
Biochemistry, Genetics and Molecular Biology 6 5%
Psychology 6 5%
Other 13 10%
Unknown 56 45%